# Older adult participation in cancer clinical trials: A systematic review of barriers and interventions

Source: https://onco.cc/key-papers/paper-sedrak-ca-cancer-j-clin/  
OnCo record `paper-sedrak-ca-cancer-j-clin` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Paper cited by one bottleneck page, indexed on Europe PMC as PubMed record 33002206 and published in CA: A Cancer Journal for Clinicians; the citing page links this DOI, which is how the record was matched.

## Summary

Cancer is a disease of aging and, as the world's population ages, the number of older persons with cancer is increasing and will make up a growing share of the oncology population in virtually every country. Despite this, older patients remain vastly underrepresented in research that sets the standards for cancer treatments. Consequently, most of what we know about cancer therapeutics is based on clinical trials conducted in younger, healthier patients, and effective strategies to improve clinical trial participation of older adults with cancer remain sparse. For this systematic review, the authors evaluated published studies regarding barriers to participation and interventions to improve participation of older adults in cancer trials. The quality of the available evidence was low and, despite a literature describing multifaceted barriers, only one intervention study aimed to increase enrollment of older adults in trials. The findings starkly amplify the paucity of evidence-based, effective strategies to improve participation of this underrepresented population in cancer trials. Within these limitations, the authors provide their opinion on how the current cancer research infrastructure must be modified to accommodate the needs of older patients. Several underused solutions are offered to expand clinical trials to include older adults with cancer. However, as currently constructed, these recommendations alone will not solve the evidence gap in geriatric oncology, and efforts are needed to meet older and frail adults where they are by expanding clinical trials designed specifically for this population and leveraging real-world data.

Indexed on Europe PMC as PubMed record 33002206 (DOI 10.3322/caac.21638). Matched by DOI alone: one bottleneck page cites this DOI among its external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: CA: A Cancer Journal for Clinicians
- Year: 2021
- DOI: 10.3322/caac.21638
- Authors: Sedrak MS, Freedman RA, Cohen HJ, et al.
- What it means: One bottleneck page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
- Caveats: Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper.

## Sources

- CA Cancer J Clin 2021: https://doi.org/10.3322/caac.21638
- PubMed: https://pubmed.ncbi.nlm.nih.gov/33002206/
- Europe PMC: https://europepmc.org/article/MED/33002206

## Connected records

- bottlenecks: [Older and multimorbid patients are excluded and undertreated](https://onco.cc/bottlenecks/b-aging-comorbidity/)
- journals: [CA: A Cancer Journal for Clinicians](https://onco.cc/journals/ca-cancer-journal/)

---
JSON: https://onco.cc/api/v1/entities/paper-sedrak-ca-cancer-j-clin.json